Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hulin

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Blood|August 10, 1999
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trialT Facon, J L Harousseau, F Maloisel, et al.
International Journal of Cardiology|June 21, 2012
Renal complications correlate with electrical atrial vulnerability hallmarks in type 2 diabetic patientsD Montaigne, O Bailloeuil, C Hulin-Delmotte, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
Journal of Medical Economics|October 31, 2015
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myelomaS Z Usmani, J D Cavenagh, A R Belch, et al.
Diabetes & Metabolism|March 16, 2018
No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetesP Barbieux, B György, E Gand, et al.
Leukemia|April 30, 2010
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trialP Moreau, C Hulin, G Marit, et al.
Leukemia|August 10, 2012
Minor clone provides a reservoir for relapse in multiple myelomaF Magrangeas, H Avet-Loiseau, W Gouraud, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Ejhaem|February 2, 2026
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive CohortA Coste, S Godet, S Manier, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Blood|August 10, 1999
Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trialT Facon, J L Harousseau, F Maloisel, et al.
International Journal of Cardiology|June 21, 2012
Renal complications correlate with electrical atrial vulnerability hallmarks in type 2 diabetic patientsD Montaigne, O Bailloeuil, C Hulin-Delmotte, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
Journal of Medical Economics|October 31, 2015
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myelomaS Z Usmani, J D Cavenagh, A R Belch, et al.
Diabetes & Metabolism|March 16, 2018
No prognostic role of a GWAS-derived genetic risk score in renal outcomes for patients from French cohorts with type 1 and type 2 diabetesP Barbieux, B György, E Gand, et al.
Leukemia|April 30, 2010
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trialP Moreau, C Hulin, G Marit, et al.
Leukemia|August 10, 2012
Minor clone provides a reservoir for relapse in multiple myelomaF Magrangeas, H Avet-Loiseau, W Gouraud, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Ejhaem|February 2, 2026
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive CohortA Coste, S Godet, S Manier, et al.
Pageof 5